Navidea Biopharmaceuticals (NAVB)
(Delayed Data from OTC)
$0.00 USD
0.00 (0.00%)
Updated Jun 14, 2024 03:28 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Navidea Biopharmaceuticals, Inc. [NAVB]
Reports for Purchase
Showing records 21 - 40 ( 41 total )
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Licenses E-IACFT Imaging Agent for Parkinson?s Disease
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Licenses E-IACFT Imaging Agent for Parkinson?s Disease
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Data Comparing AZD4694 to C-PiB Presented at the Alzheimer?s Association Conference
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Data Comparing AZD4694 to C-PiB Presented at the Alzheimer?s Association Conference
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
We are placing Navidea under review due to the departure of the covering analyst
Provider: RODMAN & RENSHAW, CO.
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Phase 1 and 2 Data Underscores AZD4694 Potential and Supports a Phase 3 Trial
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Phase 1 and 2 Data Underscores AZD4694 Potential and Supports a Phase 3 Trial
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
1Q12 UPDATE - HEAD AND NECK CANCER DATA HIGHLIGHTS LYMPHOSEEK POTENTIAL
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
1Q12 UPDATE - HEAD AND NECK CANCER DATA HIGHLIGHTS LYMPHOSEEK POTENTIAL
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Biotechnology -SUMMARIES FROM PRESENTATIONS OF COMPANIES UNDER COVERAGE OR REVIEW
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Biotechnology -SUMMARIES FROM PRESENTATIONS OF COMPANIES UNDER COVERAGE OR REVIEW
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
Lowering our rating to Neutral from Speculative Buy
Provider: Taglich Brothers, Inc.
Analyst: NOBILE J
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
4Q11 RESULTS HOT TO TROT - LYMPHOSEEK COMMERCIALIZATION PLAN ON TARGET
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
4Q11 RESULTS HOT TO TROT - LYMPHOSEEK COMMERCIALIZATION PLAN ON TARGET
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
PIPELINE BOLSTERED - CASH POSITION SOLID - APPROVAL AND PARTNERSHIP COMING
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Navidea Biopharmaceuticals, Inc.
Industry: Medical - Instruments
PIPELINE BOLSTERED - CASH POSITION SOLID - APPROVAL AND PARTNERSHIP COMING
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R